Novadiol

Biopharmaceutical company developing an IP based drug at low cost and low risk with near term exit possible after completion of Phase I and FDA meeting.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Shawnee, KS, US
  • Currency USD
  • Founded June 2012
  • Employees 3
  • Incorporation Type C-corp
  • Website novadiol.com

Company Summary

Novadiol is a Kansas City based biopharmaceutical company developing a proprietary prescription drug at reduced risk and development expense. We are developing a next generation drug for 4-5 million patients in stage 3 and 4 chronic kidney disease (CKD) in the US. The estimated market size is $12 billion. A unique pharma opportunity offers many ways for investors to win, including an estimated return of 10X in 3-4 years.

Team

  • Thomas Krol
    Chief Develoment Officer

    Dr Krol was previously Managing Director at the Kansas Bioscience Authority (KBA), and led human health investment activities. He has more than 25 years of biopharma experience spanning multiple roles in R&D, technology assessment, marketing, L&BD for bigpharma and start-up pharma. Tom had multiple roles at Oakwood Labs, Verenta Pharmaceuticals, Pharmacia-Pfizer, Searle, Sanofi-Aventis and predecessor companies, including Marion Laboratories.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free